Cyprumed GmbH MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales milestones INNSBRUCK, Austria, April 15, 2025 (GLOBE NEWSWIRE) — Cyprumed GmbH, a dedicated drug delivery company specializing in innovative oral peptide formulations, and